VRTX (Vertex Pharmaceuticals) Technical Analysis

VRTX Technical Analysis leverages historical price and volume data to provide real-time indicator values and signals, including RSI, MACD, Bollinger Bands, and volume, to reflect market momentum, volatility ranges, and price-volume dynamics. It also integrates market sentiment metrics such as the VIX volatility index, Advance-Decline ratio (A/D ratio), and Put/Call options ratio for broader market context. Multi-timeframe views span from minute intervals to daily, weekly, and monthly charts, making it easy to track indicator behavior across periods. Key support and resistance levels are displayed alongside current prices, calculated via pivots, Fibonacci retracements, and historical extremes to offer an immediate overview of market structure.
VRTX
VRTX

Vertex Pharmaceuticals

$500.32+2.06%
Today's High$501.57
Today's Low$489.00
Today's Open$490.20
Yesterday's Close$490.20

VRTX (Vertex Pharmaceuticals) Technical Analysis Overview

AI CreationAs of July 1, 2026, Vertex Pharmaceuticals (VRTX) is showing strong bullish movement. The MACD level of 13.7771 confirms a golden cross with a buy signal, indicating sustained upward momentum, while the RSI(14) reading of 71.4238 sits in the overbought zone (>70), reflecting robust bullish energy. The moving average system displays consistent bullish alignment, with EMA10 at 477.3086, EMA20 at 464.6166, and EMA50 at 452.7188 all signaling buy conditions, supported by SMA20 at 457.3482 and SMA200 at 442.6778, confirming a multi-timeframe uptrend structure that suggests constructive technical positioning.

Oscillators

Strong Sell
Strong Buy
Neutral
2
Sell
7
Neutral
2
Buy

Summary

Strong Sell
Strong Buy
Buy
3
Sell
8
Neutral
15
Buy

Moving Averages

Strong Sell
Strong Buy
Strong Buy
1
Sell
1
Neutral
13
Buy

VRTX (Vertex Pharmaceuticals) Live Candlestick Chart

VRTX (Vertex Pharmaceuticals) Multi-Timeframe Technical Rating

Summary1H4H1D1W
Moving Averages (15)131131131140
Oscillators (11)NeutralNeutralNeutralNeutral
RSI (14)60.072.374.166.0
MACD (12,26)Golden CrossGolden CrossGolden CrossGolden Cross

VRTX (Vertex Pharmaceuticals) Technical Indicator Interpretation

Based on 1-day closing price series

Oscillators

NameValueOperation
RSI(14)
74.1432Neutral
Stochastic %K (14, 3, 3)
92.7001Neutral
Commodity Channel Index (CCI) (20)
139.4373Sell
Average Directional Index (ADX) (14)
29.0028Neutral
Awesome Oscillator (AO)
40.4793Neutral
Momentum Indicator (10)
46.85Buy
MACD Level (12, 26)
14.9561Buy
Stochastic RSI Fast (3, 3, 14, 14)
94.6035Sell
Williams Percent Range (%R) (14)
-5.6348Neutral
Bull Bear Power (BBP)
44.1376Neutral
Ultimate Oscillator (UO) (7, 14, 28)
61.6709Neutral

Moving Averages

NameValueOperation
EMA (10)
481.7355Buy
SMA (10)
478.895Buy
EMA (20)
468.1607Buy
SMA (20)
461.1947Buy
EMA (30)
460.9087Buy
SMA (30)
452.9618Buy
EMA (50)
454.6491Buy
SMA (50)
445.1267Buy
EMA (100)
450.7682Buy
SMA (100)
453.089Buy
EMA (200)
448.007Buy
SMA (200)
443.2152Buy
Ichimoku Kinko Hyo Base Line (9, 26, 52, 26)
461.95Neutral
Volume-Weighted Moving Average (VWMA) (20)
467.6004Buy
Hull Moving Average (HMA) (9)
505.643Sell

VRTX (Vertex Pharmaceuticals) Pivot Points

Based on 1-day timeframe

PriceClassicFibonacciCamarillaWoodieDM
R3641.3033557.4233519.797628.53-
R2557.4233525.3812512.108566.21-
R1527.0767505.5855504.419544.65542.25
Pivot P473.5433473.5433473.5433482.33481.13
S1443.1967441.5012489.041460.77458.37
S2389.6633421.7055481.352398.45-
S3305.7833389.6633473.663376.89-

VRTX (Vertex Pharmaceuticals) Market Sentiment Index

Analyst Rating548.6896
Options Put/Call Ratio+84.93%
Implied Volatility (IV)33.732

VRTX (Vertex Pharmaceuticals) Deep Technical Analysis

As of July 1, 2026, Vertex Pharmaceuticals (VRTX) is exhibiting a strong bullish technical structure. The MACD level at 13.7771 confirms a golden cross with a buy signal, indicating strengthening upward momentum; the RSI(14) at 71.4238 sits in the overbought zone (>70), reflecting solid bullish energy that suggests short-term strength but also warrants caution regarding potential pullbacks. The **VRTX technical analysis** indicates that momentum is sustained across multiple timeframes, with the recent session close at 498.77 and the day's high of 499.79 underscoring intraday strength. The Average Directional Index (14) registers 26.6933 with a neutral signal, suggesting moderately weak trend strength that implies the market is transitioning from consolidation toward a more defined directional trend. The Commodity Channel Index (20) at 149.1596 shows a sell signal, and the Stochastic %K at 87.6587 displays a neutral signal, representing minority contrarian readings that diverge from the broader bullish consensus; this divergence indicates that while the primary trend is strong, some oscillators have begun to flash caution regarding overbought conditions. The moving average system reflects strong bullish alignment across multiple timeframes. EMA10 at 477.3086 trades above EMA20 (464.6166) and EMA50 (452.7188), confirming short-term uptrend structure, while SMA20 at 457.3482 provides intermediate support below price; the SMA200 at 442.6778 remains well below the current price action, anchoring the longer-term bullish trend. This consistent alignment reinforces the VRTX market analysis as constructive, with the near-term VRTX price forecast shaped by sustained upside bias across all major moving average timeframes. In terms of key levels, Fibonacci retracement reference points suggest resistance targets at 455.7946 (R1), 466.2754 (R2), and 483.24 (R3), while support levels are positioned at 421.8654 (S1), 411.3846 (S2), and 394.42 (S3). The recent session high of 499.79 and low of 488.63 frame the immediate trading range, with the close at 498.77 positioned near the upper portion of the range, providing a technical framework for assessing the VRTX price prediction. On the market breadth front, the option put/call ratio at 329.44 suggests elevated hedging activity and some defensive positioning, which may reflect profit-taking or risk management among option traders despite the bullish price structure. The analyst rating at 548.6896 indicates an overall positive lean from the research community, supporting the constructive technical backdrop and reinforcing the near-term VRTX outlook derived from the moving average and momentum indicators.

FAQ

What is the current technical rating for VRTX?

x
On the 4H timeframe, the aggregate technical rating for VRTX is Buy. This rating is dynamically aggregated from moving averages and momentum oscillators to reflect the prevailing trend direction and price velocity.

Where are the key support and resistance levels for VRTX?

x

What are the current RSI and MACD signals for VRTX?

x

How often is the VRTX technical analysis data updated?

x

Continue Exploring VRTX (Vertex Pharmaceuticals)

Risk Warning:

Traditional finance such as forex and CFDs may experience significant price fluctuations. Past performance is not a reliable indicator of future results. The vast majority of retail client accounts incur losses when trading forex and CFDs. Please ensure you fully understand how forex and CFDs operate and assess whether you are able to bear the risk of substantial losses. Even with stop-loss orders, your losses may exceed your initial deposit. Therefore, you should not engage in speculative trading with funds you cannot afford to lose, and you should ensure you are fully aware of the risks involved. The information provided by Gate is general in nature and does not take into account your investment objectives, financial situation, or specific needs. The content and prices on this website must not be interpreted as personal investment advice. Please ensure you fully understand the risks involved and seek independent professional advice where necessary. Gate reserves the right to terminate services at its sole discretion at any time. Gate is not liable for any losses resulting from such termination, including losses caused by closing positions at unfavorable market prices or forced liquidation. For more information, please refer to our Risk Warning.

Disclaimer:

Gate only provides trade execution services. Any information, reports, opinions, comments, or other materials obtained from Gate, its employees, Gate-provided analytical tools, or third-party research do not constitute investment advice and should not be relied upon for investment decisions. You agree to do your own research and verify external information sources before making any investment. You further agree that Gate shall not be held liable for any loss or damage (including but not limited to loss of profits) arising directly or indirectly from the use of or reliance on such information. Nothing contained in any reports shall be interpreted as an explicit or implied promise, guarantee, or indication of profit, nor does it guarantee that losses can be limited or avoided. Please also note that data related to traditional finance such as forex and CFDs (e.g., real-time prices) displayed on this page is sourced from third parties, is provided for reference only, and is offered on an "as-is" basis without any representations or warranties of any kind, express or implied. Any third-party website links provided are not under Gate's control. Gate assumes no responsibility for the reliability or accuracy of such third-party websites or their content. For further details, please refer to our User Agreement.